GLUCOSCAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 27m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLUCOSCAN is an injectable small-molecule diagnostic agent approved by Bristol Myers Squibb in 1978. The specific indication and mechanism of action are not publicly documented in available data. This product is approaching loss of exclusivity and represents a legacy injectable from the late 1970s era.
LOE Approaching
As a legacy product approaching exclusivity loss with minimal current commercial investment, roles are likely limited to maintenance support and regulatory compliance rather than growth-focused expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GLUCOSCAN offers minimal growth opportunity given zero linked job openings and LOE-approaching lifecycle status. This role suits professionals seeking stable, low-visibility legacy product management or those transitioning toward post-LOE strategy and regulatory optimization.
Product Manager (Maintenance)Regulatory Affairs Specialist
Worked on GLUCOSCAN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.